#LGVN Longeveron Announces Engagement of Lucid Capital Markets
https://www.stocktitan.net/news/LGVN/longeveron-announces-engagement-of-lucid-capital-qddvytptcorp.html?utm_source=stocktitan-bluesky&utm_medium=social
https://www.stocktitan.net/news/LGVN/longeveron-announces-engagement-of-lucid-capital-qddvytptcorp.html?utm_source=stocktitan-bluesky&utm_medium=social
Longeveron Announces Engagement of Lucid Capital Markets
Longeveron (NASDAQ: LGVN) has retained Lucid Capital Markets as its financial advisor to explore potential strategic opportunities for the company. Those opportunities include a potential business combination; the engagement is exploratory.
www.stocktitan.net
October 28, 2026 at 1:15 PM
#LGVN Longeveron Announces Engagement of Lucid Capital Markets
https://www.stocktitan.net/news/LGVN/longeveron-announces-engagement-of-lucid-capital-qddvytptcorp.html?utm_source=stocktitan-bluesky&utm_medium=social
https://www.stocktitan.net/news/LGVN/longeveron-announces-engagement-of-lucid-capital-qddvytptcorp.html?utm_source=stocktitan-bluesky&utm_medium=social
$LGVN Oct 28, 2026: Longeveron retained Lucid Capital Markets as financial advisor to explore strategic opportunities, including a potential business combination. No transaction has been announced.
https://www.merlintrader.com/longeveron-lgvn-stock-hub/
https://www.merlintrader.com/longeveron-lgvn-stock-hub/
Longeveron ($LGVN): Frailty And XPRIZE After ELPIS II
Longeveron after the ELPIS II miss: frailty and XPRIZE data, Alzheimer’s analyses, cash guided into Q4 2026, dilution and the review of all options.
www.merlintrader.com
October 28, 2026 at 3:52 PM
$LGVN Oct 28, 2026: Longeveron retained Lucid Capital Markets as financial advisor to explore strategic opportunities, including a potential business combination. No transaction has been announced.
https://www.merlintrader.com/longeveron-lgvn-stock-hub/
https://www.merlintrader.com/longeveron-lgvn-stock-hub/
#$LGVN weekly close $1.67 (+4.4% w/w), below SMA50 $3.90 / below SMA200 $6.64, RSI 31.2. Support $1.31, resistance $2.69. Broad market sell-off Friday.
Oct 26: ELPIS II update, primary missed, MACE secondary significant.
New hub updated: www.merlintrader.com/longeveron-l...
Oct 26: ELPIS II update, primary missed, MACE secondary significant.
New hub updated: www.merlintrader.com/longeveron-l...
November 1, 2026 at 2:21 PM
#$LGVN weekly close $1.67 (+4.4% w/w), below SMA50 $3.90 / below SMA200 $6.64, RSI 31.2. Support $1.31, resistance $2.69. Broad market sell-off Friday.
Oct 26: ELPIS II update, primary missed, MACE secondary significant.
New hub updated: www.merlintrader.com/longeveron-l...
Oct 26: ELPIS II update, primary missed, MACE secondary significant.
New hub updated: www.merlintrader.com/longeveron-l...
$LGVN 🤝
Longeveron Inc. retained Lucid Capital Markets, LLC as financial advisor to explore strategic opportunities, including a potential business combination.
Timely market event
More market highlights:
https://rayvio.app/dashboard/?utm_source=lifatpt
Longeveron Inc. retained Lucid Capital Markets, LLC as financial advisor to explore strategic opportunities, including a potential business combination.
Timely market event
More market highlights:
https://rayvio.app/dashboard/?utm_source=lifatpt
October 28, 2026 at 1:16 PM
$LGVN 🤝
Longeveron Inc. retained Lucid Capital Markets, LLC as financial advisor to explore strategic opportunities, including a potential business combination.
Timely market event
More market highlights:
https://rayvio.app/dashboard/?utm_source=lifatpt
Longeveron Inc. retained Lucid Capital Markets, LLC as financial advisor to explore strategic opportunities, including a potential business combination.
Timely market event
More market highlights:
https://rayvio.app/dashboard/?utm_source=lifatpt
#LGVN Longeveron Announces Updated Results from ELPIS II Phase 2b Clinical Trial Evaluating Laromestrocel as a Potential Treat…
https://www.stocktitan.net/news/LGVN/longeveron-announces-updated-results-from-elpis-ii-phase-2b-clinical-373shzdmqql0.html?utm_source=stocktitan-bluesky&utm_medium=social
https://www.stocktitan.net/news/LGVN/longeveron-announces-updated-results-from-elpis-ii-phase-2b-clinical-373shzdmqql0.html?utm_source=stocktitan-bluesky&utm_medium=social
Longeveron Announces Updated Results from ELPIS II Phase 2b Clinical Trial Evaluating Laromestrocel as a Potential Treatment for Hypoplastic Left Heart Syndrome (HLHS)
Stock Titan provides an ultra-fast stock market news feed and multiple tools for traders and investors.
www.stocktitan.net
October 26, 2026 at 1:15 PM
#LGVN Longeveron Announces Updated Results from ELPIS II Phase 2b Clinical Trial Evaluating Laromestrocel as a Potential Treat…
https://www.stocktitan.net/news/LGVN/longeveron-announces-updated-results-from-elpis-ii-phase-2b-clinical-373shzdmqql0.html?utm_source=stocktitan-bluesky&utm_medium=social
https://www.stocktitan.net/news/LGVN/longeveron-announces-updated-results-from-elpis-ii-phase-2b-clinical-373shzdmqql0.html?utm_source=stocktitan-bluesky&utm_medium=social
$LGVN updated ELPIS II: the primary endpoint was not met, but MACE was 1 vs 8 (p=0.043) on a secondary endpoint. Presentation planned for AHA on November 8.
Not investment advice.
https://www.merlintrader.com/longeveron-lgvn-stock-hub/
Not investment advice.
https://www.merlintrader.com/longeveron-lgvn-stock-hub/
October 26, 2026 at 8:38 PM
$LGVN updated ELPIS II: the primary endpoint was not met, but MACE was 1 vs 8 (p=0.043) on a secondary endpoint. Presentation planned for AHA on November 8.
Not investment advice.
https://www.merlintrader.com/longeveron-lgvn-stock-hub/
Not investment advice.
https://www.merlintrader.com/longeveron-lgvn-stock-hub/
🚨 $LGVN
On October 26, 2026, Longeveron Inc. a clinical-stage biotechnology company developing cellular therapies for life-threatening, rare pediatric and chronic aging-related conditions, issued a press release announcing updated results from ELPIS II, its Phase 2b clinical trial evaluating the ...
On October 26, 2026, Longeveron Inc. a clinical-stage biotechnology company developing cellular therapies for life-threatening, rare pediatric and chronic aging-related conditions, issued a press release announcing updated results from ELPIS II, its Phase 2b clinical trial evaluating the ...
SEC Filing: LGVN
Click to view the official SEC document.
www.sec.gov
October 26, 2026 at 8:45 PM
🚨 $LGVN
On October 26, 2026, Longeveron Inc. a clinical-stage biotechnology company developing cellular therapies for life-threatening, rare pediatric and chronic aging-related conditions, issued a press release announcing updated results from ELPIS II, its Phase 2b clinical trial evaluating the ...
On October 26, 2026, Longeveron Inc. a clinical-stage biotechnology company developing cellular therapies for life-threatening, rare pediatric and chronic aging-related conditions, issued a press release announcing updated results from ELPIS II, its Phase 2b clinical trial evaluating the ...
A post-hoc analysis of the CLEAR MIND trial on 49 participants showed Lomecel-B slowed neuroinflammation in the hippocampus and temporal/parietal cortex.
#Longeveron #StemCellTherapy #AlzheimerS
#Longeveron #StemCellTherapy #AlzheimerS
p<0.001 in the left hippocampus
Source: Longevity.Technology
realfeedapp.com
October 17, 2026 at 6:00 AM
A post-hoc analysis of the CLEAR MIND trial on 49 participants showed Lomecel-B slowed neuroinflammation in the hippocampus and temporal/parietal cortex.
#Longeveron #StemCellTherapy #AlzheimerS
#Longeveron #StemCellTherapy #AlzheimerS
October 14, 2026: Longeveron's chief medical officer, Dr. Nataliya Agafonova, stepped down; the 8-K names no successor. $LGVN
https://www.merlintrader.com/longeveron-lgvn-stock-hub/
https://www.merlintrader.com/longeveron-lgvn-stock-hub/
Longeveron ($LGVN): Frailty And XPRIZE After ELPIS II
Longeveron after the ELPIS II miss: frailty and XPRIZE data, Alzheimer’s analyses, cash guided into Q4 2026, dilution and the review of all options.
www.merlintrader.com
October 15, 2026 at 3:21 PM
October 14, 2026: Longeveron's chief medical officer, Dr. Nataliya Agafonova, stepped down; the 8-K names no successor. $LGVN
https://www.merlintrader.com/longeveron-lgvn-stock-hub/
https://www.merlintrader.com/longeveron-lgvn-stock-hub/
Longeveron Inc. (0001721484) (Filer) (cik: 0001721484) filed an 8-K update with an Item 5.02. See the filing at https://www.sec.gov/Archives/edgar/data/1721484/000121390026109411/0001213900-26-109411-index.htm
October 14, 2026 at 8:14 PM
Longeveron Inc. (0001721484) (Filer) (cik: 0001721484) filed an 8-K update with an Item 5.02. See the filing at https://www.sec.gov/Archives/edgar/data/1721484/000121390026109411/0001213900-26-109411-index.htm
🚨 $LGVN
(b) On October 7, 2026, Dr. Nataliya Agafonova informed management of Longeveron Inc. of her decision to step down as Chief Medical Officer, to become effective October 14, 2026. 1 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly cause...
(b) On October 7, 2026, Dr. Nataliya Agafonova informed management of Longeveron Inc. of her decision to step down as Chief Medical Officer, to become effective October 14, 2026. 1 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly cause...
SEC Filing: LGVN
Click to view the official SEC document.
www.sec.gov
October 14, 2026 at 8:02 PM
🚨 $LGVN
(b) On October 7, 2026, Dr. Nataliya Agafonova informed management of Longeveron Inc. of her decision to step down as Chief Medical Officer, to become effective October 14, 2026. 1 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly cause...
(b) On October 7, 2026, Dr. Nataliya Agafonova informed management of Longeveron Inc. of her decision to step down as Chief Medical Officer, to become effective October 14, 2026. 1 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly cause...
After ELPIS II: can frailty and XPRIZE carry laromestrocel? Cash is the clock.
Longeveron (#$LGVN) Stock Hub: Can Frailty and XPRIZE Carry Laromestrocel After ELPIS II?
Catalysts + risks: www.merlintrader.com/longeveron-l...
Longeveron (#$LGVN) Stock Hub: Can Frailty and XPRIZE Carry Laromestrocel After ELPIS II?
Catalysts + risks: www.merlintrader.com/longeveron-l...
October 4, 2026 at 7:34 PM
After ELPIS II: can frailty and XPRIZE carry laromestrocel? Cash is the clock.
Longeveron (#$LGVN) Stock Hub: Can Frailty and XPRIZE Carry Laromestrocel After ELPIS II?
Catalysts + risks: www.merlintrader.com/longeveron-l...
Longeveron (#$LGVN) Stock Hub: Can Frailty and XPRIZE Carry Laromestrocel After ELPIS II?
Catalysts + risks: www.merlintrader.com/longeveron-l...
Our Phase 2a Alzheimer's trial (49 participants) showed laromestrocel significantly reduced neuroinflammation in brain regions like the hippocampus (p<0.001). Calming these damaging brain responses may help protect function.
New Analysis of Laromestrocel Phase 2a Data in Alzheimer's Disease Suggests Reduced Neuroinflammatio
Longeveron Inc. announced new data analysis from its Phase 2a clinical trial (CLEAR MIND study) for laromestrocel, a cell therapy for Alzheimer's disease. The analysis indicates that treatment with la
www.biospace.com
October 1, 2026 at 8:02 AM
Our Phase 2a Alzheimer's trial (49 participants) showed laromestrocel significantly reduced neuroinflammation in brain regions like the hippocampus (p<0.001). Calming these damaging brain responses may help protect function.
#LGVN Longeveron to Participate in Three Longevity/Aging Investment Conferences
https://www.stocktitan.net/news/LGVN/longeveron-to-participate-in-three-longevity-aging-investment-lq4zqfsdb7ki.html?utm_source=stocktitan-bluesky&utm_medium=social
https://www.stocktitan.net/news/LGVN/longeveron-to-participate-in-three-longevity-aging-investment-lq4zqfsdb7ki.html?utm_source=stocktitan-bluesky&utm_medium=social
Longeveron to Participate in Three Longevity/Aging Investment Conferences
Stock Titan provides an ultra-fast stock market news feed and multiple tools for traders and investors.
www.stocktitan.net
September 30, 2026 at 8:05 PM
#LGVN Longeveron to Participate in Three Longevity/Aging Investment Conferences
https://www.stocktitan.net/news/LGVN/longeveron-to-participate-in-three-longevity-aging-investment-lq4zqfsdb7ki.html?utm_source=stocktitan-bluesky&utm_medium=social
https://www.stocktitan.net/news/LGVN/longeveron-to-participate-in-three-longevity-aging-investment-lq4zqfsdb7ki.html?utm_source=stocktitan-bluesky&utm_medium=social
⚠️ $LGVN Longeveron: ELPIS II Phase 2b trial missed primary endpoint (RVEF improvement, p=0.8336); no deaths in treated arm but MACE reduction not statistically significant; exploring options to maximize shareholder value [HIGH RISK]
September 23, 2026 at 10:00 PM
⚠️ $LGVN Longeveron: ELPIS II Phase 2b trial missed primary endpoint (RVEF improvement, p=0.8336); no deaths in treated arm but MACE reduction not statistically significant; exploring options to maximize shareholder value [HIGH RISK]
🚨 $LGVN
On September 16, 2026, Longeveron Inc. a clinical-stage biotechnology company developing cellular therapies for life-threatening, rare pediatric and chronic aging-related conditions, issued a press release announcing topline results from ELPIS II, its Phase 2b clinical trial evaluating th...
On September 16, 2026, Longeveron Inc. a clinical-stage biotechnology company developing cellular therapies for life-threatening, rare pediatric and chronic aging-related conditions, issued a press release announcing topline results from ELPIS II, its Phase 2b clinical trial evaluating th...
SEC Filing: LGVN
Click to view the official SEC document.
www.sec.gov
September 23, 2026 at 8:04 PM
🚨 $LGVN
On September 16, 2026, Longeveron Inc. a clinical-stage biotechnology company developing cellular therapies for life-threatening, rare pediatric and chronic aging-related conditions, issued a press release announcing topline results from ELPIS II, its Phase 2b clinical trial evaluating th...
On September 16, 2026, Longeveron Inc. a clinical-stage biotechnology company developing cellular therapies for life-threatening, rare pediatric and chronic aging-related conditions, issued a press release announcing topline results from ELPIS II, its Phase 2b clinical trial evaluating th...
ICYMI: Weekly #regenerative reads: Longeveron MSC trial misses primary endpoint, cool CRISPR ancestor VIPR, FDA staffing woes, more ipscell.com/2026/09/week... #stemcell
Weekly reads: Longeveron MSC trial disappoints, CRISPR ancestor VIPR, distinct human brain progenitors, FDA staffing woes - The Niche
Biologist discusses Weekly regenerative news including Longeveron trial disappoints, CRISPR ancestor VIPR, distinct human brain progenitors.
ipscell.com
September 22, 2026 at 1:25 AM
ICYMI: Weekly #regenerative reads: Longeveron MSC trial misses primary endpoint, cool CRISPR ancestor VIPR, FDA staffing woes, more ipscell.com/2026/09/week... #stemcell
Longeveron's ELPIS II trial in hypoplastic left heart syndrome missed its primary RVEF endpoint at 12 months. Exploratory analysis flagged fewer cardiovascular events in treated infants, warranting closer inspection.
Longeveron HLHS stem cell trial misses primary endpoint
ELPIS II did not meet its RVEF primary endpoint at 12 months, but exploratory data showed fewer cardiovascular events in treated infants.
biotech.disruptsmedia.com
September 22, 2026 at 6:51 AM
Longeveron's ELPIS II trial in hypoplastic left heart syndrome missed its primary RVEF endpoint at 12 months. Exploratory analysis flagged fewer cardiovascular events in treated infants, warranting closer inspection.
Weekly #regenerative reads: Longeveron MSC trial misses primary endpoint, CRISPR ancestor VIPR, distinct human brain progenitors, FDA staffing woes ipscell.com/2026/09/week... #stemcells
Weekly reads: Longeveron MSC trial disappoints, CRISPR ancestor VIPR, distinct human brain progenitors, FDA staffing woes - The Niche
Biologist discusses Weekly regenerative news including Longeveron trial disappoints, CRISPR ancestor VIPR, distinct human brain progenitors.
ipscell.com
September 20, 2026 at 2:01 PM
Weekly #regenerative reads: Longeveron MSC trial misses primary endpoint, CRISPR ancestor VIPR, distinct human brain progenitors, FDA staffing woes ipscell.com/2026/09/week... #stemcells
Longeveron (#$LGVN) Stock Hub
Free Biotech Catalyst Calendar on Merlintrader.
www.merlintrader.com/longeveron-l...
Free Biotech Catalyst Calendar on Merlintrader.
www.merlintrader.com/longeveron-l...
September 19, 2026 at 7:57 PM
Longeveron (#$LGVN) Stock Hub
Free Biotech Catalyst Calendar on Merlintrader.
www.merlintrader.com/longeveron-l...
Free Biotech Catalyst Calendar on Merlintrader.
www.merlintrader.com/longeveron-l...
Longeveron explores strategic options after therapy fails mid-stage trial for infant heart condition reut.rs/4yKzdvx
Longeveron explores strategic options after therapy fails mid-stage trial for infant heart condition
Longeveron on Wednesday said it would explore strategic options after its experimental stem cell therapy failed to meet the main goal of a mid-stage trial for a rare infant heart condition.
reut.rs
September 16, 2026 at 11:15 PM
Longeveron explores strategic options after therapy fails mid-stage trial for infant heart condition reut.rs/4yKzdvx
🚀 Zacks Small Cap Research - LGVN Posts Disappointing Trial Results
🔎 Read the full update:
➡️https://theminingnews.com/zacks-small-cap-research-lgvn-posts-disappointing-trial-results/
#LGVN #Lon#LGVNo#Longeveronr#LaromestrocelP#HLHS##ELPISII##Phase2br#AlzheimersDiseasea#AgingRelatedFrailtya href="/hashtag/R" class="hover:underline text-blue-600 dark:text-sky-400 no-card-link">#R href="/hashtag/MACE" class="hover:underline text-blue-600 dark:text-sky-400 no-card-link">#MACE
🔎 Read the full update:
➡️https://theminingnews.com/zacks-small-cap-research-lgvn-posts-disappointing-trial-results/
#LGVN #Lon#LGVNo#Longeveronr#LaromestrocelP#HLHS##ELPISII##Phase2br#AlzheimersDiseasea#AgingRelatedFrailtya href="/hashtag/R" class="hover:underline text-blue-600 dark:text-sky-400 no-card-link">#R href="/hashtag/MACE" class="hover:underline text-blue-600 dark:text-sky-400 no-card-link">#MACE
September 17, 2026 at 3:56 PM
🚀 Zacks Small Cap Research - LGVN Posts Disappointing Trial Results
🔎 Read the full update:
➡️https://theminingnews.com/zacks-small-cap-research-lgvn-posts-disappointing-trial-results/
#LGVN #Lon#LGVNo#Longeveronr#LaromestrocelP#HLHS##ELPISII##Phase2br#AlzheimersDiseasea#AgingRelatedFrailtya href="/hashtag/R" class="hover:underline text-blue-600 dark:text-sky-400 no-card-link">#R href="/hashtag/MACE" class="hover:underline text-blue-600 dark:text-sky-400 no-card-link">#MACE
🔎 Read the full update:
➡️https://theminingnews.com/zacks-small-cap-research-lgvn-posts-disappointing-trial-results/
#LGVN #Lon#LGVNo#Longeveronr#LaromestrocelP#HLHS##ELPISII##Phase2br#AlzheimersDiseasea#AgingRelatedFrailtya href="/hashtag/R" class="hover:underline text-blue-600 dark:text-sky-400 no-card-link">#R href="/hashtag/MACE" class="hover:underline text-blue-600 dark:text-sky-400 no-card-link">#MACE
ELPIS II missed its primary endpoint in HLHS. #$LGVN plans an FDA talk, cost cuts, and a strategic review as cash runs into Q4 2026. notreload.xyz/xy/longevero...
Longeveron Explores Options After HLHS Stem-Cell Fail
ELPIS II missed its primary endpoint in HLHS. Longeveron plans an FDA talk, cost cuts, and a strategic review as cash runs into Q4 2026.
notreload.xyz
September 17, 2026 at 9:38 AM
ELPIS II missed its primary endpoint in HLHS. #$LGVN plans an FDA talk, cost cuts, and a strategic review as cash runs into Q4 2026. notreload.xyz/xy/longevero...